Ocular Therapeutix (OCUL) Long-Term Debt Issuances (2017 - 2019)
Ocular Therapeutix's quarterly Long-Term Debt Issuances came in at -$70000.0 in Q2 2019, down 100.19% quarter-over-quarter from $37.3 million in Q1 2019.
Ocular Therapeutix has reported Long-Term Debt Issuances for 2 years, with the latest figure at -$70000.0 in Q2 2019.
- For the quarter ending Q2 2019, Long-Term Debt Issuances changed N/A year-over-year to -$70000.0; the trailing twelve-month figure through Sep 2021 stood at -$70000.0 (changed N/A YoY), and the FY2023 full-year result was $82.5 million, changed N/A from the prior year.
- Long-Term Debt Issuances for Q2 2019 stood at -$70000.0, down from $37.3 million in the prior quarter.
- The five-year high for Long-Term Debt Issuances was $37.3 million in Q1 2019, with the low at -$70000.0 in Q2 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.73 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Ocular Therapeutix | 1.99 Bn | 1.99 Bn | 9.46 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | -70,000.00 |
| Jun 30, 2019 | -70,000.00 |
| Mar 31, 2019 | 37.35 Mn |
| Mar 31, 2019 | 37.35 Mn |
| Mar 31, 2017 | 3.70 Mn |
| Mar 31, 2017 | 3.70 Mn |